Published in Biotech Business Week, March 8th, 2004
Second quarter earnings improved over the first quarter's break-even results, reflecting higher sales in the second quarter and higher gross margins. Year-to-date results improved from a loss of $416,000 for the first half of fiscal 2003 to a net income of $387,000 for the first half of fiscal 2004.
Lower production costs in 2004 resulted in a $937,000 improvement in gross margins versus the prior...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.